Patents by Inventor Christoph H. Ladel
Christoph H. Ladel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230258659Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 1, 2022Publication date: August 17, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230251271Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 7, 2022Publication date: August 10, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20220378981Abstract: The present invention provides a new method related to regenerative medicine for the treatment of cartilage disorders, osteoarthritis and cartilage injury in particular. More particularly, it relates to an FGF-18 compound for use in tissue engineering and graft procedures, such as osteochondral or cartilage transplantation or autologous chondrocyte implantation (ACI).Type: ApplicationFiled: June 16, 2022Publication date: December 1, 2022Inventors: Christoph H. LADEL, Hans GUEHRING, Anne GIGOUT
-
Patent number: 11513128Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: GrantFiled: September 28, 2018Date of Patent: November 29, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Patent number: 11467169Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: GrantFiled: September 28, 2018Date of Patent: October 11, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Publication number: 20220184180Abstract: The invention pertains to active compounds, in particular FGF-18 compounds, for use in the treatment of patients affected with a cartilage disorder, preferably osteoarthritis (OA), in particular for the treatment of patients who are at risk of rapid progression of the disorder.Type: ApplicationFiled: February 7, 2020Publication date: June 16, 2022Inventors: CHRISTOPH H. LADEL, HANS GUEHRING
-
Publication number: 20220047674Abstract: The present invention relates to pharmacogenetics, more specifically to strategies involving biomarkers associated with the clinical response to a compound before or during treatment of a cartilage disorder, such as osteoarthritis. The present invention more particularly relates to the combination of JSW measurements and level of specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used in strategies such as patients' enrichment in clinical trials, patients' selection strategy before or during treatment or for adapting the treatment of a patient in the frame of treatments for cartilage disorder, such as osteoarthritis.Type: ApplicationFiled: September 9, 2019Publication date: February 17, 2022Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231680Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231681Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20200222454Abstract: The present invention relates to the treatment of osteoarthritic pain and to the slowing down of the structural osteoarthritis progression in a patient having osteoarthritis. More particularly, it relates to a physiological compound for use according to particular treatment regimens. Specifically, it concerns a treatment scheme comprising weekly administration for three or four times of a physiological compound per treatment cycle.Type: ApplicationFiled: September 26, 2018Publication date: July 16, 2020Inventors: CHRISTOPH H. LADEL, HANS GUEHRING
-
Patent number: 10086112Abstract: The invention relates to the field of pharmaceutical compositions. More particularly it is directed to substance delivery system (or implant), such as scaffolds and membranes, comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects.Type: GrantFiled: February 20, 2015Date of Patent: October 2, 2018Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring
-
Publication number: 20180236032Abstract: The present invention relates to the use of an FGF-18 compound in combination with a further active ingredient, selected from the group of an inhibitor of IL-6, an inhibitor of IL-6 receptor, an inhibitor of NGF or a botulinum toxin compound. Said composition can be used for the treatment of a cartilage disorder such as osteoarthritis or cartilage injury.Type: ApplicationFiled: August 11, 2016Publication date: August 23, 2018Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE GIGOUT, CHRISTIAN BRENNEIS
-
Patent number: 9889179Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 3 weeks, 4 weeks or 5 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-adminsitration of an anti-inflammatory drug.Type: GrantFiled: February 20, 2015Date of Patent: February 13, 2018Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring
-
Patent number: 9724388Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administration every 2 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-administration of a anti-inflammatory drug.Type: GrantFiled: February 20, 2015Date of Patent: August 8, 2017Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring
-
Publication number: 20170072017Abstract: The present invention provides a new dosing regimen for administration of FGF18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 3 weeks, 4 weeks or 5 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-administration of an anti-inflammatory drug.Type: ApplicationFiled: February 20, 2015Publication date: March 16, 2017Applicant: MERCK PATENT GMBHInventors: CHRISTOPH H. LADEL, HANS GUEHRING
-
Publication number: 20170056474Abstract: The present invention provides a new dosing regimen for administration of FGF18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 2 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-administration of an anti-inflammatory drug.Type: ApplicationFiled: February 20, 2015Publication date: March 2, 2017Applicant: MERCK PATENT GMBHInventors: CHRISTOPH H. LADEL, HANS GUEHRING
-
Publication number: 20170056554Abstract: The present invention provides a new method related to regenerative medicine for the treatment of cartilage disorders, osteoarthritis and cartilage injury in particular. More particularly, it relates to an FGF-18 compound for use in tissue engineering and graft procedures, such as osteochondral or cartilage transplantation or autologous chondrocyte implantation (ACI).Type: ApplicationFiled: February 20, 2015Publication date: March 2, 2017Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE GIGOUT
-
Publication number: 20170056560Abstract: The invention relates to the field of pharmaceutical compositions. More particularly it is directed to substance delivery system (or implant), such as scaffolds and membranes, comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects.Type: ApplicationFiled: February 20, 2015Publication date: March 2, 2017Inventors: CHRISTOPH H. LADEL, HANS GUEHRING
-
Patent number: 8207115Abstract: This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.Type: GrantFiled: August 24, 2007Date of Patent: June 26, 2012Assignee: Ares Trading S.A.Inventors: Alberto Gimona, Christoph H. Ladel, Elmar Vom Baur
-
Publication number: 20100016223Abstract: This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens and for the manufacture of a medicament for the treatment of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.Type: ApplicationFiled: August 24, 2007Publication date: January 21, 2010Applicant: Ares Trading S.A.Inventors: Alberto Gimona, Christoph H. Ladel, Elmar Vom Baur